Anti-CGRP monoclonal antibodies in migraine: current perspectives.

摘要: Migraine is a highly disabling neurological pain disorder in which management frequently problematic. Most abortive and preventative treatments employed are classically non-specific, their efficacy safety tolerability often unsatisfactory. Mechanism-based therapies are, therefore, needed. Calcitonin gene-related peptide (CGRP) recognized as crucial the pathophysiology of migraine, new compounds that target have been increasingly explored recent years. First tested were CGRP receptor antagonists; they proved effective acute migraine treatment several trials, but discontinued due to liver toxicity long-term administration. Monoclonal antibodies against (LY2951742, ALD-403, LBR-101/TEV-48125) or its (AMG334) subsequently developed. As reviewed this study, numerous phase 1 2 trials preliminary results 3 shown good safety/tolerability profile prevention, especially high frequent episodic chronic forms. Being macromolecules, these mAbs not suitable for oral administration; however, intravenous subcutaneous delivery can be performed at relatively low frequency-every month even quarterly-which enhances patients' compliance. Although all migraineurs respond treatment, longer administration periods will needed assess effects, so far obtained extraordinarily promising. The future introduction on market probably represent turning point prevention similar represented by triptans migraine.